Genmab — Januar 2025
-
Teknisk: Genmab presser på nyt teknisk brud op gennem 100 dags MA, næste test opad i https://proinvestor.com/investornyt/1264286/teknisk-genmab-presser-pa-nyt-teknisk-brud-op-gennem-100-dags-ma-naeste-test-opad-i
-
Godmorgen
-
Aktier/korrektionsrisiko: Kan investorerne gemme sig i dansk life science ? https://proinvestor.com/boards/124109
-
Fra Børsen i dag "Hun har tilmed et godt øje til biotekaktien Genmab, der handler 60 pct. billigere end sin historik. Investorer er pressede over patentudløbet på den vigtige indtægtskilde Darzalex, og nu afventer afgørende nyt om den mulige arvtager til kræftmidlet, Hexabody-CD38.
Genmabs partner Janssen, der er en del af amerikanske Johnson & Johnson, har en partnerskabsoption på lægemidlet. Janssen har endnu ikke udnyttet optionen. Afgørelsen ventes i marts, pointerer Michelle Nørgaard -
aktiestrateg i Jyske Bank. “Markedet fokuserer udelukkende på nyt om Hexabody-CD38, og det mener vi er fejlagtigt. Vi ser stadig et pænt potentiale i Genmab. Aktien er faldet så meget, at du får hele deres pipeline og faktisk også nogle lancerede produkter til nul kroner,” siger hun og tilføjer:
“Forhåbentligt kan udviklingen vende i aktien, hvis der kommer en partnerskabsaftale. Så vil aktien nok stige med 20-25 pct.” https://borsen.dk/nyheder/investor/c25-pa-tilbud-her-er-de-billigste-aktier?
-
Det må godt inspirere "datteren" Johnson & Johnson rygtes tæt på milliardopkøb https://borsen.dk/nyheder/virksomheder/johnson-johnson-rygtes-taet-pa-milliardopkob?b_source=borsen&b_medium=row_0&b_campaign=list_1
-
Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy https://jitc.bmj.com/content/13/1/e010331
-
We demonstrate that a combination of CD3 bsAbs with tumor-specific vaccination improves survival against primary tumors and, importantly, also induces durable antitumor responses that confer protection from rechallenge in immunologically “hot” as well as “cold” solid tumor models.
This study provides a strong rationale for the combination of CD3 bsAbs and tumor-specific vaccination. In light of recent clinical successes of the therapeutic messenger RNA-based cancer vaccines, we advocate furthe
-
New trial : A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors https://clinicaltrials.gov/study/NCT06771921
-
Target not disclosed yet. 'estimated trial duration is 8 months for an individual participant /
The treatment duration will be an estimated 3-month treatment period > makes me think this is for a very serious disease? and maybe expect relative toxic drug? -
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology https://www.businesswire.com/news/home/20250113347375/en/AbCellera-Expands-Collaboration-with-AbbVie-to-Develop-Novel-T-Cell-Engagers-for-Oncology?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork
-
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma https://www.prnewswire.com/news-releases/simcere-zaiming-and-abbvie-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-in-multiple-myeloma-302349311.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind